PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Japan Development, Global Vaccine Business Unit, Takeda Pharmaceutical Company Ltd, Japan. Electronic address: taisei.masuda@takeda.com.\', \'Japan Medical and Policy Affairs, Medical Affairs Office, Global Vaccine Business Unit, Takeda Pharmaceutical Company Ltd, Japan. Electronic address: kyoko.murakami@takeda.com.\', \'Statistical and Quantitative Sciences, Data Sciences Institute, Takeda Pharmaceutical Company Ltd, Japan. Electronic address: kenkichi.sugiura@takeda.com.\', \'Statistical and Quantitative Sciences, Data Sciences Institute, Takeda Pharmaceutical Company Ltd, Japan. Electronic address: sho.sakui@takeda.com.\', \'Clinical Development, Global Vaccine Business Unit, Takeda Pharmaceutical International Ag, Switzerland. Electronic address: ron.schuring@takeda.com.\', \'Japan Development, Global Vaccine Business Unit, Takeda Pharmaceutical Company Ltd, Japan. Electronic address: mitsuhiro.mori@takeda.com.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0264-410X(22)00164-510.1016/j.vaccine.2022.02.030
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 35177302
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
?:title
  • A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35177302>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35177302>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all